The report offers a comprehensive analysis of over 40 companies and more than 50 drugs within the competitive landscape for sickle cell disease (SCD). This report evaluates therapeutics based on product type, stage of development, route of administration, and molecule type, while also shedding light on inactive pipeline products.
Geographical Coverage: Global
Sickle cell disease is a severe hereditary condition affecting hemoglobin in red blood cells. People with SCD inherit a gene defect from each parent, leading to the presence of atypical hemoglobin molecules, which in turn cause red blood cells to adopt a sickle shape. This distortion leads to several complications, including anemia due to the rapid destruction of red blood cells.
Testing for SCD can occur pre-birth or at any age, with varying methods depending on patient age. Available treatments aim to prevent crises, alleviate symptoms, and forestall complications, utilizing pain management medications, blood transfusions, and possibly bone marrow transplants. Researchers are pursuing groundbreaking gene therapies to amend the genetic defect or promote the production of fetal hemoglobin.